But drugmakers have argued this could suck supplies out of Greece if Athens leaves the euro and prices in euro terms fall sharply. The European Association of Euro Pharmaceutical Companies, representing firms involved in this so-called parallel trade, said drugmakers were wrong to say supplies could be in jeopardy if Europe did not take such emergency...» Read More
Operating profit at Denmark's Novo Nordisk slipped 2 percent last year but still beat analysts' expectations due to strong sales growth in the US and China, company CEO Lars Rebien told "Worldwide Exchange" on Thursday.
AstraZeneca gave a cautious outlook for the year ahead on Thursday after meeting analyst forecasts with a 3 percent fall in 2007 earnings, and said market conditions remained challenging.
This morning on "Squawk on the Street" I did a pharma earnings round-up report and I topped it by saying the sector could remain under pressure today because two major American drug companies--Bristol-Myers Squibb and Wyeth-- missed earnings expectations and lowered their 2008 guidance.
Bristol-Myers Squibb Thursday reported a loss from continuing operations as special charges more than offset strong sales growth of its array of prescription drugs.
Medicis Pharmaceutical said on Thursday the U.S. Food and Drug Administration had decided that the company's Biologics License Application for the botulinum toxin type A, called Reloxin, in aesthetics was incomplete.
It's a booyah-free zone. There goes Swifty!Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
At 1 pm ET today the embargo was supposed to lift on an article in the scientific journal "Nature" that we got advanced word on early this morning. We were set to post the write-through about it at that time on our web site.
European pharmaceutical Roche reported a better-than-expected 25 percent increase in fourth-quarter net profit Wednesday on strong sales of its cancer drugs, despite lower sales of its key influenza drug Tamiflu.
Dow component Merck beat the Street with fourth quarter results on earnings per share (revenue was a sliver below the analyst consensus) and reaffirmed its earnings guidance for this year. Maybe the beaten-down stock is falling victim to another pre-Fed interest rate decision market downdraft...
Merck on Wednesday reported a fourth-quarter loss due to charges from a costly settlement related to its withdrawn Vioxx arthritis drug, but results soundly beat Wall Street forecastsand lifted its shares 2 percent.
"Dendreonians" were hoping the Provenge controversy might come up for discussion at the House Energy and Commerce Committee's Subcommittee on Oversight and Investigations hearing today.
Eli Lilly posted a higher fourth-quarter profit Tuesday. The pharmaceutical firm cited lower taxes and better-than-expected drug sales -- especially sales of its newer formulations for diabetes and cancer. John Lechleiter, president and chief operating officer -- and Lilly's CEO as of April 1 -- gave CNBC his strong earnings outlook.
Direct-to-consumer pharmaceutical advertising is everywhere in American media because it works. Generally speaking, it drives patients to ask/tell their doctors to prescribe a particular medication.
Eli Lilly Tuesday said fourth-quarter profit rose on lower taxes and better-than-expected sales of its medicines, including its newer treatments for depression, diabetes and cancer.
In what I would describe as a pretty extraordinary filing with the Securities and Exchange Commission, Schering-Plough is putting in black and white the date and time that senior level executives were informed about the results of the controversial ENHANCE study of the cholesterol drug Vytorin.
A $4 billion company I've never covered before, Inverness Medical Innovations, is making news this morning with a $900 million acquisition of another company I've never covered--Matria Healthcare, Inc. But that's not why I'm blogging about Inverness.
I listened in to the hour-long Food and Drug Administration conference call with reporters regarding Vytorin, and I wanted to pass along a few highlights...
In the wake of my semantic disagreement with Amgen over whether it beat, met or missed its earnings pre-announcement earlier this month, analysts are putting out research notes to clients on the company's results, guidance and new drug data and blog readers are sending emails about my take on the full year 2007 number.
I just got back to my desk after doing a breaking news alert on Amgen's earnings. To sum up, I characterized the report as a mixed bag. The anemia drug sales weren't as bad as expected. Overall revenue was higher than consensus. And fourth quarter earnings per share was three cents higher than the Street.
Amgen reported on Thursday that its fourth-quarter profit edged higher, on a reversal of declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.